PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
(Thomson Reuters ONE) -
REGULATED INFORMATION
GHENT, Belgium, 15 November 2017 - Ablynx NV [Euronext Brussels and Nasdaq:
ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May
2007 regarding the publication of major shareholdings in issuers whose
securities are admitted to trading on a regulated market (the "Transparency
Law"), that it received a notification of shareholdings from C.H. Boehringer
Sohn AG & Co KG on 13 November 2017.
C.H. Boehringer Sohn AG & Co KG notified Ablynx that it has been passively
downward crossing the lowest threshold on 27 October 2017.
The notification contains the following information:
* Reason for the notification: downward crossing of the lowest threshold;
passive crossing of a threshold
* Notification by: a parent undertaking or a controlling person
* Persons subject to the notification requirement: C.H. Boehringer Sohn AG &
Co KG, BIR&D Beteiligungs GmbH
* Date on which threshold is crossed: 27 October 2017
* Threshold that is crossed: 3%
* Denominator: 73,006,144 (on 27 October 2017)
* Details of the notification: - (no details required when downward crossing
the lowest threshold)
* Chain of controlled undertakings through which the holding is effectively
being held: C.H. Boehringer Sohn AG & Co KG controls BIR&D Beteiligungs
GmbH. C.H. Boehringer Sohn AG & Co KG is not controlled
* Additional information: Boehringer Ingelheim International GmbH has been
replaced by BIR&D Beteiligungs GmbH as a result of a group internal
reallocation
More information is provided in the transparency notification. Full versions of
the transparency notifications are available on Ablynx website, under the
section Investors.
The Articles of the Association of Ablynx NV provide for shareholders
notification threshold of 3%, 5% or a multiple of 5% of the total number of
existing voting rights.
About Ablynx
Ablynx is a biopharmaceutical company engaged in the development of Nanobodies,
proprietary therapeutic proteins based on single-domain antibody fragments,
which combine the advantages of conventional antibody drugs with some of the
features of small-molecule drugs. Ablynx is dedicated to creating new medicines
which will make a real difference to society. Today, the Company has more than
45 proprietary and partnered programmes in development in various therapeutic
areas including inflammation, haematology, immuno-oncology, oncology and
respiratory disease. The Company has collaborations with multiple pharmaceutical
companies including AbbVie; Boehringer Ingelheim; Eddingpharm; Merck & Co.,
Inc., Kenilworth, New Jersey, USA; Merck KGaA; Novartis; Novo Nordisk; Sanofi
and Taisho Pharmaceuticals. The Company is headquartered in Ghent, Belgium. More
information can be found on www.ablynx.com.
For more information, please contact
Ablynx:
Dr Edwin Moses
CEO
t: +32 (0)9 262 00 07
m: +32 (0)473 39 50 68
e: edwin.moses(at)ablynx.com
Lies Vanneste
Director Investor Relations
t: +32 (0)9 262 01 37
m: +32 (0)498 05 35 79
e: lies.vanneste(at)ablynx.com
Follow us on Twitter (at)AblynxABLX
Ablynx media relations:
Consilium Strategic Communications
Mary-Jane Elliott, Philippa Gardner, Sukaina Virji
t: +44 (0)20 3709 5700
e: ablynx(at)consilium-comms.com
Disclaimer
Certain statements, beliefs and opinions in this press release are forward-
looking, which reflect the Company or, as appropriate, the Company directors'
current expectations and projections about future events. By their nature,
forward-looking statements involve a number of risks, uncertainties and
assumptions that could cause actual results or events to differ materially from
those expressed or implied by the forward-looking statements. These risks,
uncertainties and assumptions could adversely affect the outcome and financial
effects of the plans and events described herein. A multitude of factors
including, but not limited to, changes in demand, competition and technology,
can cause actual events, performance or results to differ significantly from any
anticipated development. Forward looking statements contained in this press
release regarding past trends or activities should not be taken as a
representation that such trends or activities will continue in the future. As a
result, the Company expressly disclaims any obligation or undertaking to release
any update or revisions to any forward-looking statements in this press release
as a result of any change in expectations or any change in events, conditions,
assumptions or circumstances on which these forward-looking statements are
based. Neither the Company nor its advisers or representatives nor any of its
parent or subsidiary undertakings or any such person's officers or employees
guarantees that the assumptions underlying such forward-looking statements are
free from errors nor does either accept any responsibility for the future
accuracy of the forward-looking statements contained in this press release or
the actual occurrence of the forecasted developments. You should not place undue
reliance on forward-looking statements, which speak only as of the date of this
press release.
pdf version of the press release:
http://hugin.info/137912/R/2149798/825074.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Ablynx via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
" alt="Rockcliff to Update National Instrument 43-101 Resource at Talbot Additional Geophysical Survey Warranted below Talbot DepositDatum: 15.11.2017 - 07:00 Uhr
Sprache: Deutsch
News-ID 568193
Anzahl Zeichen: 6462
contact information:
Town:
Ghent/Zwijnaarde
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 195 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")"
steht unter der journalistisch-redaktionellen Verantwortung von
Ablynx (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
